Advicenne S.A.
PAR: ALDVI.PA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Laurent Cassedanne
- Employees
- 21
- Headquarters
- Paris, France
- IPO year
- 2017
- Market cap
- €12.7M
- Website
- https://www.advicenne.com
Loading ALDVI…
Loading profile data…Frequently asked questions about ALDVI
What does Advicenne S.A. (ALDVI.PA) do?
Advicenne S.A., a specialty pharmaceutical company, develops and commercializes treatments for nephrology. Its lead product candidate is Sibnayal for the treatment of distal renal tubular acidosis, as well as for the treatment of cystinuria. Advicenne S.A. was founded in 2007 and is headquartered in Paris, France.
Where does ALDVI.PA trade?
Advicenne S.A. (ALDVI.PA) trades on the Euronext Paris.
What sector is ALDVI.PA in?
Advicenne S.A. (ALDVI.PA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Advicenne S.A.?
Laurent Cassedanne is the chief executive officer of Advicenne S.A. (ALDVI.PA).
Where is Advicenne S.A. headquartered?
Advicenne S.A. is headquartered in France.
Does ALDVI.PA pay a dividend?
Advicenne S.A. (ALDVI.PA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ALDVI.PA go public?
Advicenne S.A. (ALDVI.PA) completed its initial public offering in 2017.